UNSPSC 51333413: Ziprasidone hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-2-indolinone monohydrochloride, monohydrate but more generally known as ziprasidone hydrochloride, which bears US NIH Compound Identifier 60853.

UNSPSC 51333413 Ziprasidone hydrochloride is a Commodity code that nominally identifies a single antipsychotic pharmaceutical product, but recent state and local procurement activity under this code shows little direct alignment with the code's specific drug classification. The three recent opportunities posted to this code span naloxone procurement, therapeutic pharmacy initiatives exploring direct-to-manufacturer contracting, and multi-source generic pharmaceutical supply agreements—none of which target ziprasidone specifically. This mismatch suggests the code may be used as a catch-all categorization for pharmaceutical procurement rather than a precise product identifier in state and local systems. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work in practice covers emergency response medications, generic pharmaceutical sourcing, and direct manufacturer contracting arrangements for prescription fulfillment and cost management across state and local government health programs.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County released an IFB on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. Texas HHS posted an RFI on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, through MMCAP, issued an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. The code shows limited recent activity specifically targeting ziprasidone; procurement professionals should verify the code's applicability before pursuing opportunities posted under it.